Details for New Drug Application (NDA): 208623
✉ Email this page to a colleague
The generic ingredient in GALAFOLD is migalastat hydrochloride. There is one drug master file entry for this compound. One supplier is listed for this compound. Additional details are available on the migalastat hydrochloride profile page.
Summary for 208623
| Tradename: | GALAFOLD |
| Applicant: | Amicus Therap Us |
| Ingredient: | migalastat hydrochloride |
| Patents: | 66 |
DrugPatentWatch® Estimated Loss of Exclusivity (LOE) Date for 208623
Generic Entry Date for 208623*:
Constraining patent/regulatory exclusivity:
Dosage:
CAPSULE;ORAL |
*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.
Suppliers and Packaging for NDA: 208623
| Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
|---|---|---|---|---|---|---|---|---|
| GALAFOLD | migalastat hydrochloride | CAPSULE;ORAL | 208623 | NDA | Amicus Therapeutics US, LLC | 71904-100 | 71904-100-01 | 14 BLISTER PACK in 1 CARTON (71904-100-01) / 1 CAPSULE in 1 BLISTER PACK |
Profile for product number 001
| Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | EQ 123MG BASE | ||||
| Approval Date: | Aug 10, 2018 | TE: | RLD: | Yes | |||||
| Patent: | 10,076,514 | Patent Expiration: | Mar 15, 2037 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | THE TREATMENT OF FABRY PATIENTS | ||||||||
| Patent: | 10,251,873 | Patent Expiration: | May 30, 2038 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | THE TREATMENT OF FABRY PATIENTS | ||||||||
| Patent: | 10,383,864 | Patent Expiration: | May 16, 2027 | Product Flag? | Substance Flag? | Delist Request? | |||
| Patented Use: | THE TREATMENT OF FABRY PATIENTS | ||||||||
Complete Access Available with Subscription
